Pro-life commentator John Mize argues that Democrats' gains in the November 3 midterm elections make the movement's fight to restrict abortion more urgent, not less. Writing in an opinion piece for Fox News, Mize says the shift in congressional majorities puts two years of pro-life federal progress at risk and calls on activists to press for specific legislative and regulatory action.
Mize's central concern is federal funding and conscience protections. The Hyde Amendment bars taxpayer dollars from paying for most abortions, and the Weldon Amendment shields healthcare entities that decline to provide abortions from discrimination. Mize notes that both riders survived a 2021 House committee bill that left them out, a fact he presents as evidence of how vulnerable they can be when Congress changes hands. He cites a 2026 Knights of Columbus and Marist poll in which 54 percent of respondents opposed taxpayer funding of abortion, and 63 percent supported conscience protections for providers.
Mize also devotes significant attention to the Women's Health Protection Act, which would codify abortion access before viability and override state limits. According to the piece, opponents argue the measure would strip away rules such as ultrasound requirements and waiting periods. The bill passed the House in the previous Congress but stalled in the Senate, where it fell short of the 60 votes needed to advance. Mize warns that the new Congress could move to eliminate the filibuster, which would change that calculation and make the legislation far more achievable.
Beyond Capitol Hill, Mize points to pending regulatory and legal fronts. The Food and Drug Administration has a review of mifepristone underway, with final results expected by March 2027. Mize urges the agency to restore in-person dispensing requirements for the drug. He also calls for rescinding a Biden-era Office of Legal Counsel opinion related to the Comstock Act, and he identifies mail-order abortion pills as a priority target for pro-life efforts.
Several questions remain open. It is not yet clear whether Democrats will drop the filibuster, whether the FDA review will produce new restrictions, or how the Supreme Court will rule in a challenge to abortion pills brought by Republican leaders. Mize's column makes clear that the pro-life movement sees the coming months as a decisive period, with the outcome of these fights likely to shape federal abortion policy for years.